# Evaluation of Therapeutic Equivalence - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/evaluation-of-therapeutic-equivalence/cd67148c-495a-4ce8-be79-e37f4769b3ae

> FDA guidance document: Evaluation of Therapeutic Equivalence. Issue date: July 21, 2022. Get complete insights and analysis.

---

## Details

- Title: Evaluation of Therapeutic Equivalence
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2022-07-21
- Comment Close Date: 2022-09-19
- Last Changed: 2023-01-11
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-0528">FDA-2022-D-0528</a>

## Related Documents

- [New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers](https://www.globalkeysolutions.net/guidances/guidance-document/new-clinical-investigation-exclusivity-3-year-exclusivity-for-drug-products-questions-and-answers/19bf8380-085c-46d8-a480-d28b1c37d3de)
- [Sameness Evaluations in an ANDA — Active Ingredients](https://www.globalkeysolutions.net/guidances/guidance-document/sameness-evaluations-in-an-anda-active-ingredients/56e63be0-f1f7-48cf-90e1-c9eb340486ef)
- [In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs](https://www.globalkeysolutions.net/guidances/guidance-document/in-vitro-release-test-studies-for-topical-drug-products-submitted-in-andas/c7ff8356-0869-42f7-a5dc-76e32fe0380b)